# Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

> **NCT03912402** · PHASE2 · UNKNOWN · sponsor: **Biocad** · enrollment: 49 (estimated)

## Conditions studied

- Cervical Cancer
- Cervical Cancer Metastatic
- Cervical Cancer Recurrent

## Interventions

- **BIOLOGICAL:** BCD-100
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin (or carboplatin)

## Key facts

- **NCT ID:** NCT03912402
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-25
- **Primary completion:** 2020-07-07
- **Final completion:** 2020-07-07
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2019-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912402, "Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03912402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*